Last reviewed · How we verify
Ruxolitinib Cream
At a glance
| Generic name | Ruxolitinib Cream |
|---|---|
| Also known as | INCB018424 Phosphate Cream, Opzelura, INCB018424 phosphate cream, INCB018424, INCB018424 cream |
| Sponsor | Incyte Corporation |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa (PHASE1)
- A Study to Assess the Safety and Efficacy of Ruxolitinib Cream in Participants With Genital Vitiligo (PHASE2)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2) (PHASE3)
- Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS1) (PHASE3)
- Study of the Safety and Efficacy of Ruxolitinib Cream for Non-Sclerotic Chronic Cutaneous Graft-Versus-Host Disease (PHASE2)
- Comparative Effectiveness of Ruxolitinib Monotherapy Versus Its Combination With Tacrolimus and Corticosteroids in the Management of Vitiligo: A Randomized Controlled Trial (PHASE4)
- A Real-world Study on the Influencing Factors of Efficacy of Ruxolitinib Cream in Vitiligo
- The Purpose of This Study is to Evaluate the Effects of Ruxolitinib Cream on Adults With Atopic Dermatitis Experiencing Sleep Disturbance. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ruxolitinib Cream CI brief — competitive landscape report
- Ruxolitinib Cream updates RSS · CI watch RSS
- Incyte Corporation portfolio CI